A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (Suzhou) Co. Ltd.
AstraZeneca
Coherus Oncology, Inc.
BeOne Medicines
Lepu Biopharma Co., Ltd.
Akeso
Shanghai Henlius Biotech
Compass Therapeutics
Exelixis
AstraZeneca
AstraZeneca
Eisai Inc.
AstraZeneca
Genentech, Inc.
Zymeworks BC Inc.
Akeso
ABK Biomedical
Akeso
Boston Scientific Corporation
ViroMissile, Inc.
Eisai Inc.
Eisai Inc.
Seagen Inc.
Boston Scientific Corporation
Bristol-Myers Squibb
AstraZeneca
SEED Therapeutics, Inc.
MedImmune LLC
Jiangsu HengRui Medicine Co., Ltd.
Alnylam Pharmaceuticals
DualityBio Inc.
Merck Sharp & Dohme LLC
MacroGenics
Coherus Oncology, Inc.
Merck Sharp & Dohme LLC
Hoffmann-La Roche
SAPU NANO (US) LLC
Philips Clinical & Medical Affairs Global
Jiangsu Simcere Pharmaceutical Co., Ltd.
Guerbet
SOFIE
Changchun GeneScience Pharmaceutical Co., Ltd.
AbbVie
Wondercel Biotech (ShenZhen)
inTumo Therapeutics, Inc.
AstraZeneca
ImmunityBio, Inc.
AstraZeneca
Indaptus Therapeutics, Inc
Ocellaris Pharma, Inc.